Fibroblast growth factor 21 mutations
US-9023791-B2 · May 5, 2015 · US
Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9631004B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9631004-B2 |
| Application number | US-201615215329-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 20, 2016 |
| Priority date | Oct 24, 2014 |
| Publication date | Apr 25, 2017 |
| Grant date | Apr 25, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
First claim
Opening claim text (preview).
What is claimed is: 1. A modified FGF-21 polypeptide comprising a polypeptide having at least 96% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202. 2. The modified FGF-21 polypeptide of claim 1 , wherein said modified FGF-21 polypeptide comprises a polypeptide having at least 97% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202. 3. The modified FGF-21 polypeptide of claim 2 , wherein said modified FGF-21 polypeptide comprises a polypeptide having at least 99% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202. 4. The modified FGF-21 polypeptide of claim 1 , wherein said modified FGF-21 polypeptide is linked to a half-life extending moiety. 5. The modified FGF-21 polypeptide of claim 4 , wherein said half-life extending moiety comprises a poly(ethylene glycol). 6. The modified FGF-21 polypeptide of claim 5 , wherein said poly(ethylene glycol) has an average molecular weight between 10 kDa and 40 kDa. 7. The modified FGF-21 polypeptide of claim 5 , wherein said poly(ethylene glycol) has an average molecular weight of about 30 kDa. 8. The modified FGF-21 polypeptide of claim 4 , wherein said modified FGF-21 polypeptide is linked to a half-life extending moiety via a para-acetyl-L-phenylalanine in the modified FGF-21 polypeptide. 9. A composition comprising the modified FGF-21 polypeptide of claim 1 and a pharmaceutically acceptable carrier or excipient. 10. A modified FGF-21 polypeptide comprising a polypeptide having the amino acid sequence of SEQ ID NO: 202, wherein said modified FGF-21 polypeptide is linked to a half-life extending moiety via the para-acetyl-L-phenylalanine in the modified FGF-21 polypeptide. 11. The modified FGF-21 polypeptide of claim 10 , wherein the half-life extending moiety comprises a water soluble polymer. 12. The modified FGF-21 polypeptide of claim 11 , wherein the half-life extending moiety comprises a poly(ethylene glycol) having an average molecular weight between 20 kDa and 40 kDa. 13. A composition comprising the modified FGF-21 polypeptide of claim 10 and a pharmaceutically acceptable carrier or excipient. 14. A modified FGF-21 polypeptide comprising a polypeptide having the amino acid sequence of SEQ ID NO: 202, wherein said modified FGF-21 polypeptide is linked to a half-life extending moiety comprising a poly(ethylene glycol) via the para-acetyl-L-phenylalanine in the modified FGF-21 polypeptide. 15. The modified FGF-21 polypeptide of claim 14 , wherein said poly(ethylene glycol) has an average molecular weight between 10 kDa and 40 kDa. 16. The modified FGF-21 polypeptide of claim 14 , wherein the para-acetyl-L-phenylalanine in the modified FGF-21 polypeptide is linked to the half-life extending moiety through an oxime linkage. 17. A composition comprising the modified FGF-21 polypeptide of claim 14 and a pharmaceutically acceptable carrier or excipient.
Assignees
Inventors
Classifications
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Drugs for disorders of the cardiovascular system · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Antihyperlipidemics · CPC title
Antiandrogens · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9631004B2 cover?
- Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07K14/50. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).